At JP Morgan, LabCorp CEO Discusses Plans for Expanded Genomic Testing | GenomeWeb

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is planning on expanding its portfolio of genomics-based diagnostics, CEO David King said this week at the JP Morgan Healthcare Conference.

"We never want to get away from the core [testing] business, because the core business is very fundamental to the delivery of healthcare and to patient care," King said in his presentation, which was webcast. "But we want to migrate the business to where we can continue to be seen as a value adder in the value chain."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.